|1.||Shore, Eileen M: 8 articles (12/2012 - 05/2006)|
|2.||Kaplan, Frederick S: 8 articles (12/2012 - 05/2006)|
|3.||Mishina, Yuji: 6 articles (04/2015 - 03/2005)|
|4.||Yu, Paul B: 6 articles (10/2014 - 12/2008)|
|5.||Cuny, Gregory D: 3 articles (10/2014 - 12/2008)|
|6.||Katagiri, Takenobu: 3 articles (06/2013 - 12/2008)|
|7.||Deng, Donna Y: 3 articles (06/2013 - 12/2008)|
|8.||Morhart, Rolf: 3 articles (12/2012 - 05/2006)|
|9.||Pignolo, Robert J: 3 articles (12/2012 - 11/2011)|
|10.||Bloch, Kenneth D: 3 articles (10/2011 - 12/2008)|
06/01/2013 - "Gain-of-function mutations in one BMP type I receptor have been identified in patients with fibrodysplasia ossificans progressiva, a rare genetic disorder that is characterized by progressive heterotopic bone formation in the skeletal muscle. "
06/01/2010 - "ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation."
01/01/2010 - "Mutations in the BMP type I receptor ALK2 were identified in patients suffering from Fibrodysplasia Ossificans Progressiva (FOP). "
12/19/2008 - "A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor."
05/01/2006 - "A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva."
|3.||Heterotopic Ossification (Ectopic Ossification)
01/01/2012 - "The ACVR1/Alk-2 gene, encoding a BMP type I receptor, is mutated in Fibrodysplasia Ossificans Progressiva, a severe form of heterotopic ossification. "
06/01/2011 - "The discovery that mildly activating mutations in ACVR1/ALK2, a bone morphogenetic protein (BMP) type I receptor, is the cause of FOP has provided opportunities to identify previously unknown functions for this receptor and for BMP signaling and to develop new diagnostic and therapeutic strategies for FOP and other more common forms of heterotopic ossification, as well as tissue engineering applications."
12/01/2008 - "These results support the role of dysregulated ALK2 kinase activity in the pathogenesis of FOP and suggest that small molecule inhibition of BMP type I receptor activity may be useful in treating FOP and heterotopic ossification syndromes associated with excessive BMP signaling."
10/09/2014 - "There are currently no effective therapies for fibrodysplasia ossificans progressiva (FOP), a debilitating and progressive heterotopic ossification disease caused by activating mutations of ACVR1 encoding the BMP type I receptor kinase ALK2. "
12/01/2012 - "Fibrodysplasia ossificans progressiva (FOP), a rare, disabling condition caused by gain-of-function mutations of a bone morphogenetic protein (BMP) type I receptor, leads to episodes of heterotopic ossification and resultant immobility. "
04/01/2015 - "We have previously reported that enhanced BMP signaling through the BMP type IA receptor (BMPR1A) in cranial neural crest cells causes craniosynostosis during postnatal development. "
06/01/2013 - "Moreover, in vivo treatment with LDN-193189, a selective chemical inhibitor of BMP type I receptor kinases, resulted in partial rescue of craniosynostosis. "
|1.||Type II Bone Morphogenetic Protein Receptors (Bone Morphogenetic Protein Receptor Type II)
|2.||Bone Morphogenetic Proteins (Bone Morphogenetic Protein)
|4.||Activin Receptors (Activin Receptor)
|8.||Glycine (Aminoacetic Acid)
|10.||Bone Morphogenetic Protein 2